ARROWHEAD PHARMACEUTICALS, INC. — Director's Dealing 2022

Jan 8, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK: 0000879407
Period of Report: 2022-01-07

Reporting Person: Anzalone Christopher Richard (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-01-07	Common Stock	M	11806	$5.19	Acquired	4057634	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-01-07	Stock Option (right to buy Common Stock)	$5.19	M	11806	Disposed	2022-02-16	Common Stock (11806)	Direct

Footnotes

F1: Includes a total of 2,300,000 shares underlying restricted stock units that may be earned based on the achievement of certain performance and/or market-based goals. If the goals are not met within the required time periods, the awards will be forfeited in part or in whole.

F2: Represents first vesting date. Option vested over four years from date of grant.

F3: Represents total stock options beneficially owned at various strike prices.